Suppr超能文献

住院患者中显著升高的丙氨酸氨基转移酶与药物性肝损伤。

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.

机构信息

Department of Pharmacy, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.

出版信息

World J Gastroenterol. 2012 Nov 7;18(41):5972-8. doi: 10.3748/wjg.v18.i41.5972.

Abstract

AIM

To identify the proportion, causes and the nature of drug-induced liver injury (DILI) in patients with notably elevated alanine aminotransferase (ALT).

METHODS

All the inpatients with ALT levels above 10 times upper limit of normal range (ULN) were retrospectively identified from a computerized clinical laboratory database at our hospital covering a 12-mo period. Relevant clinical information was obtained from medical records. Alternative causes of ALT elevations were examined for each patient, including biliary abnormality, viral hepatitis, hemodynamic injury, malignancy, DILI or undetermined and other causes. All suspected DILI cases were causality assessed using the Council for International Organizations of Medical Sciences scale, and only the cases classified as highly probable, probable, or possible were diagnosed as DILI. Comments related to the diagnosis of DILI in the medical record and in the discharge letter for each case were also examined to evaluate DILI detection by the treating doctors.

RESULTS

A total of 129 cases with ALT > 10 ULN were identified. Hemodynamic injury (n = 46, 35.7%), DILI (n = 25, 19.4%) and malignancy (n = 21, 16.3%) were the top three causes of liver injury. Peak ALT values were lower in DILI patients than in patients with hemodynamic injury (14.5 ± 5.6 ULN vs 32.5 ± 30.7 ULN, P = 0.001). Among DILI patients, one (4%) case was classified as definite, 19 (76%) cases were classified as probable and 5 (20%) as possible according to the CIOMS scale. A hepatocellular pattern was observed in 23 (92%) cases and mixed in 2 (8%). The extent of severity of liver injury was mild in 21 (84%) patients and moderate in 4 (16%). Before discharge, 10 (40%) patients were recovered and the other 15 (60%) were improved. The improved patients tended to have a higher peak ALT (808 ± 348 U/L vs 623 ± 118 U/L, P = 0.016) and shorter treatment duration before discharge (8 ± 6 d vs 28 ± 12 d, P = 0.008) compared with the recovered patients. Twenty-two drugs and 6 herbs were found associated with DILI. Antibacterials were the most common agents causing DILI in 8 (32%) cases, followed by glucocorticoids in 6 (24%) cases. Twenty-four (96%) cases received treatment of DILI with at least one adjunctive drug. Agents for treatment of DILI included anti-inflammatory drugs (e.g., glycyrrhizinate), antioxidants (e.g., glutathione, ademetionine 1,4-butanedisulfonate and tiopronin), polyene phosphatidyl choline and herbal extracts (e.g., protoporphyrin disodium and silymarin). Diagnosis of DILI was not mentioned in the discharge letter in 60% of the cases. Relative to prevalent cases and cases from wards of internal medicine, incident cases and cases from surgical wards had a higher risk of missed diagnosis in discharge letter [odds ratio (OR) 32.7, 95%CI (2.8-374.1), and OR 58.5, 95%CI (4.6-746.6), respectively].

CONCLUSION

DILI is mostly caused by use of antibacterials and glucocorticoids, and constitutes about one fifth of hospitalized patients with ALT > 10 ULN. DILI is underdiagnosed frequently.

摘要

目的

确定明显升高的丙氨酸氨基转移酶(ALT)患者中药物性肝损伤(DILI)的比例、原因和性质。

方法

从我院计算机化临床实验室数据库中回顾性确定了 ALT 水平超过正常值上限(ULN)10 倍的所有住院患者,时间范围为 12 个月。从病历中获取每位患者的其他 ALT 升高的相关病因信息,包括胆管异常、病毒性肝炎、血流动力学损伤、恶性肿瘤、DILI 或未确定和其他原因。使用国际医学组织理事会(Council for International Organizations of Medical Sciences,CIOMS)量表对所有疑似 DILI 病例进行因果关系评估,仅将被归类为高度可能、可能或很可能的病例诊断为 DILI。还检查了病历和每个病例的出院小结中与 DILI 诊断相关的评论,以评估治疗医生对 DILI 的检测。

结果

共确定了 129 例 ALT>10 ULN 的患者。血流动力学损伤(n=46,35.7%)、DILI(n=25,19.4%)和恶性肿瘤(n=21,16.3%)是导致肝损伤的前三大原因。DILI 患者的 ALT 峰值明显低于血流动力学损伤患者(14.5±5.6 ULN 比 32.5±30.7 ULN,P=0.001)。根据 CIOMS 量表,DILI 患者中有 1(4%)例被归类为明确,19(76%)例被归类为可能,5(20%)例被归类为很可能。23(92%)例为肝细胞模式,2(8%)例为混合模式。21(84%)例患者的肝损伤严重程度为轻度,4(16%)例为中度。出院前,10(40%)例患者恢复,15(60%)例患者改善。与恢复的患者相比,改善的患者的 ALT 峰值(808±348 U/L 比 623±118 U/L,P=0.016)和出院前的治疗时间(8±6 d 比 28±12 d,P=0.008)更高。发现 22 种药物和 6 种草药与 DILI 有关。抗菌药物是导致 8(32%)例 DILI 的最常见药物,其次是糖皮质激素(6 例,24%)。24(96%)例患者接受了至少一种辅助药物治疗 DILI。DILI 的治疗药物包括抗炎药(如甘草酸)、抗氧化剂(如谷胱甘肽、腺苷蛋氨酸 1,4-丁二磺酸酯和硫普罗宁)、多烯磷脂酰胆碱和草药提取物(如卟啉 disodium 和水飞蓟素)。在 60%的病例中,出院小结中未提及 DILI 的诊断。与常见病例和内科病房的病例相比,意外病例和外科病房的病例在出院小结中被误诊的风险更高[比值比(OR)32.7,95%CI(2.8-374.1)和 OR 58.5,95%CI(4.6-746.6)]。

结论

DILI 主要由使用抗菌药物和糖皮质激素引起,约占 ALT>10 ULN 的住院患者的五分之一。DILI 经常被漏诊。

相似文献

1
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
World J Gastroenterol. 2012 Nov 7;18(41):5972-8. doi: 10.3748/wjg.v18.i41.5972.
2
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Gastroenterology. 2014 Jul;147(1):109-118.e5. doi: 10.1053/j.gastro.2014.03.050. Epub 2014 Apr 1.
5
Incidence of drug-induced liver injury in medical inpatients.
Eur J Clin Pharmacol. 2005 Apr;61(2):135-43. doi: 10.1007/s00228-004-0888-z. Epub 2005 Feb 23.
9
The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Liver Int. 2015 Nov;35(11):2474-82. doi: 10.1111/liv.12834. Epub 2015 Apr 8.
10
Clinical Features and Risk Factors for Drug-Induced Liver Injury: A Retrospective Study From China.
Clin Ther. 2024 Aug;46(8):597-603. doi: 10.1016/j.clinthera.2024.04.014. Epub 2024 May 31.

引用本文的文献

1
Insights into medication-induced liver injury: Understanding and management strategies.
Toxicol Rep. 2025 Mar 1;14:101976. doi: 10.1016/j.toxrep.2025.101976. eCollection 2025 Jun.
3
Choledocholithiasis Can Present with Marked Transaminases Elevation: Systematic Review and Meta-Analysis.
Dig Dis Sci. 2023 Aug;68(8):3428-3435. doi: 10.1007/s10620-023-07981-7. Epub 2023 Jun 3.
6
Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort.
JGH Open. 2019 Jul 18;4(2):106-112. doi: 10.1002/jgh3.12224. eCollection 2020 Apr.
7
Irreversible electroporation of malignant liver tumors: Effect on laboratory values.
Oncol Lett. 2018 Sep;16(3):3881-3888. doi: 10.3892/ol.2018.9058. Epub 2018 Jul 2.
9
Clinical Features of Drug-induced Liver Injury According to Etiology.
J Korean Med Sci. 2015 Dec;30(12):1815-20. doi: 10.3346/jkms.2015.30.12.1815. Epub 2015 Nov 30.
10
MicroRNAs in Drug-induced Liver Injury.
J Clin Transl Hepatol. 2014 Sep;2(3):162-9. doi: 10.14218/JCTH.2014.00015. Epub 2014 Sep 15.

本文引用的文献

2
Hepatic protection by glycyrrhizin and inhibition of iNOS expression in concanavalin A-induced liver injury in mice.
Inflamm Res. 2009 Sep;58(9):593-9. doi: 10.1007/s00011-009-0024-8. Epub 2009 Mar 31.
3
Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006.
Hepatol Res. 2009 May;39(5):427-31. doi: 10.1111/j.1872-034X.2008.00486.x. Epub 2009 Jan 16.
4
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.
5
Practical guidelines for diagnosis and early management of drug-induced liver injury.
World J Gastroenterol. 2008 Nov 28;14(44):6774-85. doi: 10.3748/wjg.14.6774.
6
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4. doi: 10.1053/j.gastro.2008.09.011. Epub 2008 Sep 17.
7
Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.
Aliment Pharmacol Ther. 2008 May;27(9):780-9. doi: 10.1111/j.1365-2036.2008.03655.x. Epub 2008 Feb 18.
8
Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice.
Biol Pharm Bull. 2007 Oct;30(10):1898-904. doi: 10.1248/bpb.30.1898.
9
Drug-induced liver injury.
Drug Saf. 2007;30(4):277-94. doi: 10.2165/00002018-200730040-00001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验